{"id":"W4379981083","doi":"10.1002/hon.3163_t04","title":"MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VERSUS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Pharmacyclics; Seagen; BeiGene; Celgene; Gilead Sciences","keywords":"Obinutuzumab; Medicine; Lenalidomide; Rituximab; Ibrutinib; Internal medicine; Idelalisib; Oncology; Bruton's tyrosine kinase; Follicular lymphoma; Salvage therapy; Chronic lymphocytic leukemia; Lymphoma; Chemotherapy; Leukemia; Multiple myeloma; Tyrosine kinase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008970094,0.0004231625,0.002269369,0.0005058929,0.00008914436,0.00001425574,0.0003761596,0.0007443259,0.0006279781],"category_scores_gemma":[0.001963883,0.0002762247,0.000243235,0.00134947,0.0007205462,0.0001085601,0.0003217065,0.0005197274,0.0003342715],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.0102975,"about_ca_system_score_gemma":0.0112047,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002511591,"about_ca_topic_score_gemma":0.00008300647,"domain_scores_codex":[0.9953195,0.0004701317,0.001139718,0.0008333605,0.001101025,0.00113628],"domain_scores_gemma":[0.9961687,0.002071877,0.0003972844,0.0006986604,0.0002503235,0.0004131977],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.958037,0.01129886,0.0009635369,0.0004540569,0.0003514316,0.01895507,0.0002840468,0.0000369204,0.0001458701,0.0006883056,0.002528109,0.006256833],"study_design_scores_gemma":[0.9528766,0.03096653,0.001850936,0.0002272379,0.0002034145,0.0004780636,0.0003059432,0.002956979,0.0004730835,0.00003921546,0.009292231,0.0003298117],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946963,0.0001346404,0.00007269518,0.0005908808,0.000502311,0.002283371,0.0000295701,0.0001715049,0.001518754],"genre_scores_gemma":[0.9978745,0.0001285704,0.0007194811,0.0001657241,0.0001329568,0.0002373297,0.0001704506,0.00005584172,0.0005151767],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01966766,"threshold_uncertainty_score":0.999969,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06003095277318925,"score_gpt":0.3721584572127411,"score_spread":0.3121275044395518,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}